UroGen Pharma (URGN) Finished Goods (2020 - 2021)
UroGen Pharma's (URGN) quarterly Finished Goods came in at $888000.0 in Q1 2021, down 2.74% on a QoQ basis from $913000.0 in Q4 2020.
Powered by 
Analysis
UroGen Pharma (URGN) Finished Goods (2020 - 2021) Analysis & Trends
UroGen Pharma (URGN) has 2 years of Finished Goods data on file, last reported at $888000.0 in Q1 2021.
- Quarterly Finished Goods changed N/A year-over-year to $888000.0 in Q1 2021, while the trailing twelve-month figure through Mar 2021 was $888000.0 (changed N/A YoY) and the FY2020 annual result came in at $913000.0, changed N/A from the prior year.
- Finished Goods eased to $888000.0 in Q1 2021, from $913000.0 in the prior quarter.
- In the past five years, Finished Goods ranged from a high of $913000.0 in Q4 2020 to a low of $232000.0 in Q2 2020.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn |
| 10 | UroGen Pharma | 2.23 Bn | 2.12 Bn | 65.88 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Mar 31, 2021 | 888,000.00 |
| Dec 31, 2020 | 913,000.00 |
| Sep 30, 2020 | 419,000.00 |
| Jun 30, 2020 | 232,000.00 |